The electronic version of this document is currently unavailable

Active substance: lisinopril - Regulatory ... - European Medicines Agency

May 13, 2016 - EMA/388981/2016. Procedure Management and Committees Support ... Lisinopril Brown & Burk. Uk. PL 25298/0118 $ PL 25298/0119 $.

42KB Sizes 0 Downloads 248 Views

Recommend Documents

Active substance: urapidil Regulatory outcome - European Medicines ...
Feb 11, 2016 - Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5525. Send a question via our website www.ema.europa.eu/contact. © European ...

Active substance - European Medicines Agency - Europa EU
May 13, 2016 - Procedure Management and Committees Support. List of nationally authorised medicinal ... MRP UK/H/0464/002. IS/1/07/020/01. Santen Oy.

Active substance - European Medicines Agency - Europa EU
Sep 29, 2016 - Send a question via our website www.ema.europa.eu/contact. © European ... Product Name (in ... Erdomed 300 mg - Kapseln not available.

Active substance: Zafirlukast - European Medicines Agency - Europa EU
Sep 2, 2016 - Send a question via our website www.ema.europa.eu/contact. © European ... Product Name (in authorisation country) ... con film not available.

Active substance: valaciclovir Regulatory outcome - European ...
Sep 2, 2016 - THE WELLCOME FOUNDATION. LTD. GR. Valtrex 250 mg comprimidos revestidos por película. SE/H/1041/001. 2966083. LABORATORIOS WELLCOME DE. PORTUGAL LIMITADA. PT. Valtrex 250 mg comprimidos revestidos por película. SE/H/1041/001. 3131786.

Active substance: rupatadine Regulatory outcome - European ...
Feb 11, 2016 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom ... Procedure Management and Committees Support. List of ...

hydrochlorothiazide / lisinopril Regulatory outcome - European ...
Sep 29, 2016 - Send a question via our website www.ema.europa.eu/contact. © European ... Product Name (in authorisation country) ... not available. 1-19510.

Active substance: chloroquine Regulatory outcome: variation
Mar 31, 2016 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom ... Procedure Management and Committees Support. List of ...

Active substance: valaciclovir Regulatory outcome: maintenance
Sep 2, 2016 - SIGMA-TAU INDUSTRIE. FARMACEUTICHE RIUNITE. S.P.A.. IT. Valaciclovir ”Orion”. UK/H/2940/01/DC. 44083. ORION OYJ. DK. Valaciclovir ...

Active substance: testosterone undecanoate; Regulatory Outcome ...
Oct 29, 2016 - Taking into account the PRAC Assessment Report on the PSUR(s) for ... 3. Annex II. Amendments to the product information of the nationally ...

Active substance: Cefoperazone Regulatory outcome: variation
Oct 29, 2016 - Taking into account the PRAC Assessment Report on the PSUR(s) for ... 3. Annex II. Amendments to the product information of the nationally ...

Active substance: Cefoperazone Regulatory outcome: variation
Oct 29, 2016 - should be discontinued if there is persistent bleeding and no alternative explanations are identified. Package Leaflet. 2. Warnings and precautions. Cefoperazone - active substance of – may inhibit blood clotting. Serious bleedings,

Active substance: bisoprolol Regulatory outcome: maintenance
May 13, 2016 - Concor COR 1,25 mg filmom obložene tablete. SE/H/0184/001. HR-H-350108325-04. MERCK D.O.O. HR. Full application. (Article 8(3) of.

Active substance: hydromorphone Regulatory outcome: variation
Oct 29, 2016 - Amendments to be included in the relevant sections of the Product Information (new text underlined and in bold, deleted text strike through). Summary of Product Characteristics. •. Section 4.6. Prolonged use of hydromorphone during p

Active substance: Captopril-hydrochlorothiazide Regulatory outcome ...
Jan 28, 2017 - The primary analysis examined sudden death within seven days of an outpatient prescription for one of ... Package Leaflet. •. Section 2.

Active substance: hydromorphone Regulatory outcome: variation
Oct 29, 2016 - Taking into account the PRAC Assessment Report on the PSUR(s) for ... 3. Annex II. Amendments to the product information of the nationally ...

Active substance: rabeprazole - Regulatory outcome: maintenance
Jun 9, 2016 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom ... Procedure Management and Committees Support. List of ...

Active substance: ketamine Regulatory outcome: maintenance
Sep 2, 2016 - Send a question via our website www.ema.europa.eu/contact ... Ketalar 50 mg/ml injeksjonsvæske, oppløsning not available. 5724. PFIZER AS.

Notice - European Medicines Agency
Apr 28, 2017 - 2. The United Kingdom will then become a 'third country'. 3. Preparing for the withdrawal is therefore not just a matter for EU and national authorities, but also for private parties. In view of the considerable uncertainties, in parti

Report - European Medicines Agency
May 30, 2017 - Pharmaceutical companies are invited to present their pre-clinical data pertaining to ... patients per year, as many questions about the best use of ALK ... of knowledge and evidence to support the planning and regulatory.

Human Medicines Highlights Newsletter - European Medicines Agency
Mar 8, 2018 - Treatment of uterine fibroids. Haematology. New medicines authorised. • Adynovi (rurioctocog alfa pegol). Treatment and prevention of bleeding in patients with haemophilia A. New information on authorised medicines. • Feraccru (ferr

Veterinary medicines highlights 2016 - European Medicines Agency
Jan 26, 2017 - is an antiparasitic medicine that treats the Varroa mite infestation in honey-bee colonies, which is considered to be the most significant parasitic ...

Human Medicines Highlights Newsletter - European Medicines Agency
Treatment of cystine crystal deposits in the eye. New information on authorised medicines. Lucentis (ranibizumab) - change in indication. Treatment of visual ...

Human Medicines Highlights Newsletter - European Medicines Agency
The new EudraVigilance system and the electronic reporting of individual case ... the ISO/ICH E2B(R3) format: hands-on training course - October 2017 ... granted a conditional marketing authorisation on the basis of less complete clinical data ...